January 2026
The UK’s Medical Research Council Centre of Research Excellence in Clinical Trial Innovation (MRC CoRE CTI), which is being set up in partnership with the National Institute for Health and Care Research, will receive £50 million over 14 years with the ambition of transforming the clinical trial landscape:
For the first time in a while, the biotechnology industry starts a new year with momentum, much of it fuelled by clinical trial results. BioPharma Dive selects ten to watch in the first half of this year:
The European Commission has released plans intended to accelerate clinical trial approvals across the EU and cut costs by as much as 80–90% through the use of AI-enabled trials. EU average clinical trials take well over 100 days; in the UK, it’s c. 60 days. The aim is to drive that down to 47–50 days on average:
Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined one-stop- shop process for clients to advance from first-in-human (FIH) up to pivotal trials:
In a free virtual panel, industry experts will discuss practical examples and considerations for applying AI in pharma’s clinical trials. Date: 26 March 2026, Time: 3 PM GMT:
Democrat Governor Maura Healey has written to U.S. Health and Human Services Secretary Robert F. Kennedy Jr. to demand that he restore funding cuts to the National Institutes of Health (NIH) that have stopped 380 clinical trials and impacted more than 74,000 patients nationally, including 18 clinical trials and 13,000 patients in Massachusetts:
A review of an inclusive recruitment strategy that was adopted during the ‘Live Well with Parkinson’s’ trial, funded by the NIHR’s Programme Grants for Applied Research Programme:
Two of the largest clinical trials of their kind have shown that a daily dose of oral semaglutide did not delay progression of the neurodegenerative disease Alzheimer’s:
Analysis commissioned by the Department of Science, Innovation and Technology (DSIT) has found positive outcomes for UK research projects backed by the Horizon R&D programme. UK researchers secured £6.8 billion in funding through nearly 11,000 projects via the Horizon 2020 programme (H2020) from 2014-2020, including for clinical trials:
The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. The proposal is designed to incentivize U.S. drug development by tacking on higher fees for those not running phase 1 trials in the country:
